A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01611558

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:37:39.196571+00:00

Published At

2016-04-19T00:00:00+00:00

Record Updated At

2020-07-13

Results Posted At

2016-04-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2020-07-13"

protocolSection.identificationModule.nctId

"NCT01611558"

protocolSection.identificationModule.officialTitle

"A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2016-04-19"

Study condition terms

• Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.